Digi International Announces Anterix Active Solution for Industrial Connectivity at the Edge in Utilities and Critical Infrastructure
Article content
The Digi IX30 Cellular Router with Anterix Active Powers Secure, Resilient Communications for Private and Public LTE Deployments
Article content
MINNEAPOLIS — Digi International, (NASDAQ: DGII, www.digi.com), a global leader in Internet of Things (IoT) connectivity solutions, announces the market launch of Digi IX30-0EG4, an edge computing industrial IoT cellular router solution.
Article content
The Anterix Active designation reinforces Digi's commitment to helping critical infrastructure operators deploy private LTE networks that are secure, reliable, and built for the future.
Article content
Digi IX30-0EG4 has achieved the Anterix Active designation, providing full support for Anterix's nationwide 900 MHz private LTE spectrum. This industrial IoT edge computing solution is specifically designed for hazardous and mission-critical applications on both public and private LTE networks. It is tailored for energy and utilities applications such as real-time monitoring and control, smart grid automation, demand response, renewable energy integration, DERMS, and SCADA systems. Fully integrated with Digi Remote Manager ®, this solution's capabilities improve security and scalability while ensuring speed, reliability and efficiency.
Article content
Digi IX30-0EG4 is a C1D2 and NEMA TS2-rated cellular router engineered to deliver secure, reliable connectivity for industrial assets. With support from Anterix, the large holder of licensed spectrum in the 900 MHz band (896-901/935-940 MHz) throughout the contiguous United States, plus Alaska, Hawaii, and Puerto Rico — Digi IX30-0EG4 helps utility operators unlock the full potential of private LTE networks. This low-band spectrum is ideally suited for wide-area coverage, deep penetration through obstacles, and consistent performance across vast and challenging terrains. Offering a powerful combination of coverage and capacity, it supports the always-on, secure communication channels required for grid resiliency, operational visibility, and long-term infrastructure modernization.
Article content
'The Anterix Active designation reinforces Digi's commitment to helping critical infrastructure operators deploy private LTE networks that are secure, reliable, and built for the future,' said Vitaly Kurduban, Senior Product Manager at Digi International. 'Digi IX30-0EG4 provides advanced edge intelligence, streamlined integration, and ruggedized performance that is purpose-built for evolving needs — accelerating the transformation of the energy and utilities sector.'
Article content
Powered by Digi Remote Manager (Digi RM) and Digi Accelerated Linux (DAL OS), Digi IX30-0EG4 enables centralized configuration, deployment, and monitoring of mission-critical infrastructure at scale. Digi RM serves as the command center of the network, allowing operators to manage tens of thousands of distributed devices from a single interface — whether on a desktop, tablet, or smartphone. Meanwhile, DAL OS delivers secure edge programmability and interoperability with legacy serial protocols, and support for MQTT Sparkplug B — allowing seamless integration into modern SCADA, telemetry, and automation systems.
Article content
With a high density of I/O ports, Digi IX30 reduces the need for external hardware, eliminating potential failure points while simplifying deployments. Its range of SKUs includes edge compute capabilities and support for public, private, and hybrid cellular networks, offering unmatched deployment flexibility.
Article content
'We are excited to see Digi International with the Digi IX30-0EG4 industrial router continue to add to the portfolio of devices as a member of the Anterix Active Ecosystem,' said Steve Ryan, Vice President, Ecosystem and Partnerships at Anterix. 'With its proven reliability and rich feature set, Digi IX30 delivers a critical building block for utilities seeking secure, private LTE communications — particularly for applications that demand continuous uptime, edge control, and long-term adaptability.'
Article content
The Anterix 900 MHz spectrum is designed to meet the rigorous demands of utility broadband communications, offering dedicated performance, coverage, and security.
Article content
Key Features of Digi IX30 with Anterix Support:
Article content
Anterix Active designation — Full support for 900 MHz band private LTE networks
Industrial-grade ruggedness — C1D2, NEMA TS2, wide temperature range, and DIN-rail mountable
Edge intelligence and I/O — High port density, analog/digital I/O, GNSS, dual Ethernet
Digi Remote Manager — Centralized network visibility, management, and security at scale
DAL OS — Programmability, legacy protocol support, and seamless SCADA integration
Flexible deployment — Support for public, private, and hybrid LTE networks in one SKU
Article content
Digi IX30-0EG4 with Anterix Active support is available now through Digi's authorized distributors.
Article content
Article content
Article content
Article content
Article content
Contacts
Article content
Article content
Article content
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
19 minutes ago
- Globe and Mail
Do Greater Rewards Await Enterprise Products' Unit Holders?
Enterprise Products Partners EPD, through its unit buyback program, continues to return capital to unitholders. The partnership's total buyback through the 12 months ending March 2025 has reached $239 million, resulting in a cumulative repurchase of approximately $1.2 billion under its buyback program. This underscores the partnership's strong confidence in creating long-term value from its business, thereby enhancing returns for unitholders. With the market undervaluing Enterprise Products' units, allocating capital for buying back its own units is a smart move for the partnership. Thus, the remaining units are getting a bigger share of the partnership's earnings and cash flow, which is highly favorable for existing investors. EPD anticipates generating additional free cash flow starting next year. This is primarily due to the completion of some key capital projects currently under construction, which, in turn, will lower the annual growth in capital expenditures. With more capital becoming available, Enterprise Products will likely allocate a greater amount of money for repurchases, thereby accelerating capital returns. Are KMI & WMB Also Rewarding Investors Handsomely? Kinder Morgan KMI and Williams WMB are also leading midstream energy players, thereby are less vulnerable to oil and gas price volatility. Despite their stable business models, both KMI and WMB currently reward investors with lower dividend yields than the industry's composite stocks. Kinder Morgan's current dividend yield is 4.13%, lower than the industry's 5.20% yield. Williams' current dividend yield is 3.3%. EPD's Price Performance, Valuation & Estimates Units of EPD have gained 14.1% over the past year, surpassing the 13.2% improvement of the composite stocks belonging to the industry. One-Year Price Chart From a valuation standpoint, EPD trades at a trailing 12-month enterprise value to EBITDA (EV/EBITDA) of 10.00x. This is below the broader industry average of 11.39x. The Zacks Consensus Estimate for EPD's 2025 earnings hasn't been revised over the past seven days. It currently carries a Zacks Rank #4 (Sell). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Research Chief Names "Single Best Pick to Double" From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months. Free: See Our Top Stock And 4 Runners Up Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Williams Companies, Inc. (The) (WMB): Free Stock Analysis Report Enterprise Products Partners L.P. (EPD): Free Stock Analysis Report Kinder Morgan, Inc. (KMI): Free Stock Analysis Report
Globe and Mail
20 minutes ago
- Globe and Mail
JEF Q2 Earnings Meet Estimates on Solid Capital Markets, Stock Down
Jefferies Financial Group 's JEF second-quarter fiscal 2025 (ended May 31) adjusted earnings of 43 cents per share matched the Zacks Consensus Estimate. The bottom line compared unfavorably with the prior-year quarter's earnings of 67 cents per share. Results were aided by strong performance in higher capital markets revenues. However, weak performances in the investment banking (IB) and asset management business, alongside higher expenses, remain a spoilsport. The company's shares declined 2.5% in the after-market hours in light of these negatives. Net income attributable to common shareholders (GAAP basis) was $88 million, declining from $145.7 million in the prior-year quarter. Jefferies' Revenues Decline, Expenses Rise Quarterly net revenues were $1.63 billion, down 1.3% year over year. The top line surpassed the Zacks Consensus Estimate of $1.56 billion. Total non-interest expenses were $1.50 billion, up 5% from the prior-year quarter. The rise was due to an increase in almost all cost components except compensation and benefits and underwriting costs. As of May 31, 2025, book value per common share was $49.96, up from $46.57 as of May 31, 2024. Further, adjusted tangible book value per fully diluted share of $32.84 increased from $31.27. JEF's Quarterly Segment Performance Investment Banking and Capital Markets: Net revenues were $1.47 billion, falling 1.6% from the prior-year quarter. The decline was due to lower equity & debt underwriting and fixed-income performance in capital markets, partially offset by solid performance across, along with a robust performance in Equities. Asset Management: Net revenues were $154.6 million, down 1.2% from the year-ago quarter. Jefferies' Dividend Update Concurrently, Jefferies announced a quarterly cash dividend of 40 cents per share. The dividend will be paid out on Aug. 29, 2025, to shareholders as of Aug. 18. Our View on JEF Elevated expenses driven by higher compensation, alongside exposure to geopolitical risk, given its global presence, will likely hurt Jefferies' financials in the near term. Yet, a robust trading and asset management business, alongside improving IB operations, will offer support to some extent. Jefferies Financial Group Inc. Price, Consensus and EPS Surprise Jefferies Financial Group Inc. price-consensus-eps-surprise-chart | Jefferies Financial Group Inc. Quote Currently, Jefferies has a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Earnings Dates of JEF's Peers JPMorgan JPM is scheduled to report second-quarter 2025 results on July 15. Over the past seven days, the Zacks Consensus Estimate for JPMorgan's quarterly earnings has been revised marginally upward to $4.47. This indicates 1.6% growth from the prior-year quarter. (Find the latest EPS estimates and surprises on Zacks Earnings Calendar.) Bank of America BAC is slated to announce second-quarter 2025 results on July 14. Over the past seven days, the Zacks Consensus Estimate for BAC's quarterly earnings has remained unchanged at 89 cents, implying a 7.2% rise from the prior-year quarter. Research Chief Names "Single Best Pick to Double" From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months. Free: See Our Top Stock And 4 Runners Up Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. JPMorgan Chase & Co. (JPM): Free Stock Analysis Report
Globe and Mail
20 minutes ago
- Globe and Mail
Will MRK's Growing Pipeline Help Navigate the Looming Keytruda LOE?
Merck MRK has built a substantial portfolio of new products and pipeline candidates in areas like oncology, vaccines, neuroscience, and infectious disease. Merck's phase III pipeline has almost tripled since 2021, supported by in-house pipeline progress as well as the addition of candidates through M&A deals. The company is now positioned to launch around 20 new vaccines and drugs over the next few years, with many having blockbuster potential. Merck has several promising candidates in late-stage development, such as enlicitide decanoate/MK-0616, an oral PCSK9 inhibitor for hypercholesterolemia, tulisokibart, a TL1A inhibitor for ulcerative colitis, bomedemstat/MK-3543 for essential thrombocythemia, myelofibrosis and polycythemia vera and Daiichi-Sankyo-partnered antibody-drug conjugates (ADCs). Merck and Daiichi Sankyo are co-developing three DXd ADCs — patritumab deruxtecan, ifinatamab deruxtecan and raludotatug deruxtecan for several types of cancer indications. To foray into the lucrative obesity market, Merck has in-licensed global rights to an investigational oral GLP-1 receptor agonist, HS-10535, from China-based biotech Hansoh Pharma. MRK's Keytruda Faces Patent Expiration in 2028 As Merck prepares for Keytruda's eventual loss of exclusivity in 2028, the company's expanding pipeline and new products are expected to play a key role in shaping its future business mix. Besides working on various strategies to drive Keytruda's long-term growth, Merck is also pinning hopes on its new 21-valent pneumococcal conjugate vaccine, Capvaxive, and pulmonary arterial hypertension (PAH) drug, Winrevair, to boost its top line once Keytruda loses exclusivity. Both products have witnessed a strong launch so far. Merck's long-acting monoclonal antibody, Enflonsia (clesrovimab), for the prevention of respiratory syncytial virus was approved by the FDA earlier this month. Keytruda, a PD-L1 inhibitor approved for several types of cancer, generated sales of $7.21 billion in the first quarter of 2025, up 6% year over year. Our model estimates for Keytruda suggest a CAGR of 5.4% over the next three years. However, at present, it is not quite clear whether Merck's new products and pipeline candidates can help the company successfully navigate the Keytruda LOE period and potential competition for the drug. PD-L1 Inhibitors Competing With Keytruda Keytruda faces competition from other PD-L1 inhibitors, including Bristol Myers ' BMY Opdivo, Roche 's RHHBY Tecentriq and AstraZeneca 's AZN Imfinzi. BMY's Opdivo, like Keytruda, is approved across multiple cancer types, including lung, melanoma and kidney cancers. Bristol Myers recorded $2.26 billion in Opdivo sales during the first quarter of 2025, up 9% year over year. Tecentriq is Roche's leading immuno-oncology drug approved for multiple cancer indications. RHHBY recorded CHF 870 million in Tecentriq sales in the first quarter of 2025. AZN's Imfinzi generated sales of $1.26 billion in the first quarter of 2025, up 16%, driven by demand growth in lung and liver cancer indications. Imfinzi has strategically expanded its use across multiple cancer indications, strengthening AstraZeneca's oncology portfolio. MRK's Price Performance, Valuation and Estimates Year to date, shares of Merck have lost 19.9% compared with the industry 's decrease of 1.8%. From a valuation standpoint, Merck appears attractive relative to the industry. Going by the price/earnings ratio, the company's shares currently trade at 8.56 forward earnings, lower than 14.92 for the industry and its 5-year mean of 12.85. The Zacks Consensus Estimate for 2025 earnings has declined from $8.94 per share to $8.92, while the same for 2026 has decreased from $9.79 to $9.73 over the past 60 days. Merck has a Zacks Rank #4 (Sell). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Research Chief Names "Single Best Pick to Double" From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months. Free: See Our Top Stock And 4 Runners Up Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report AstraZeneca PLC (AZN): Free Stock Analysis Report Roche Holding AG (RHHBY): Free Stock Analysis Report Bristol Myers Squibb Company (BMY): Free Stock Analysis Report Merck & Co., Inc. (MRK): Free Stock Analysis Report
